Inflation type one error [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-11-08 18:15 (925 d 10:48 ago) – Posting: # 20769
Views: 2,913


Sorry for my bad english!

» Here the trouble starts (see what I wrote above). What we are doing here is actually HARKing (Hypothesizing After the Results are Known). Not exactly but we definitely generate the Null from the data. Apart from the TIE-issues every product approved by RSABE/ABEL followed its own rules. From a consumer’s perspective this is not fortunate.

Yes, we generate hypothesis, but we loss any link of TIE with reality. We form hypothesis from variance estimate, but it is only estimate we don't know real variance. I can't imagine how to definite TIE in this case.

» Not sure what you mean here. Can you elaborate?

Ofcource. It it my description of situation :-D I think that "HARKing" come to bioequivalce because it is very expencive to make BE with big samplesize or make theraputic equivalence and it is compromise between regulators and industry. And from my side HARKing is a bad statistics (yes: consumer’s perspective this is not fortunate), but it is discussible ... some persons recommending that HARKing not be taught by educators, encouraged by reviewers or editors, or practiced by authors

Complete thread:

UA Flag
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Sunday 06:04 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz